drugset / Trial / NCT05993325
Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers
RandomizedParallel-groupTriple-blindPrevention
Summary
The immunogenicity and safety of AdCLD-CoV19-1 OMI (5.0x10\^10 VP (0.5 mL)/dose/Vial) administered as a booster in healthy adults aged 19 years old and above will be evaluated. Outcome assessment will be performed in comparison with Comirnaty Bivalent.
Timeline
- Start
- 2023-11-27
- Primary completion
- 2025-03
- Completion
- 2025-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AdCLD-CoV19-1 OMI | Vaccine | 5e+10 unknown | Intramuscular |
| Comparator | Comirnaty Bivalent | Unknown | 0.1 mg/ml | Intramuscular |